KFAS
PACB icon

Keating Financial Advisory Services’s Pacific Biosciences PACB Stock Holding History

Keating Financial Advisory Services’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.52K Hold
1,500
– – ﹤0.01% 1859
2026
Q1 		$1.98K Hold
1,500
– – ﹤0.01% 1851
2025
Q4 		$2.81K Buy
+1,500
New +$2.88K ﹤0.01% 1478

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Keating Financial Advisory Services's PACB Position: Q2 2026 in Review

Keating Financial Advisory Services held its Pacific Biosciences (PACB) position steady in Q2 2026 at 1,500 shares worth $2.52K. The position accounts for ﹤0.01% of the portfolio, ranked #1859.

Keating Financial Advisory Services first reported a position in PACB in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.81K in Q4 2025. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • Keating Financial Advisory Services held 1,500 shares of Pacific Biosciences worth $2.52K as of Q2 2026.
  • Keating Financial Advisory Services left its Pacific Biosciences share count unchanged in Q2 2026.
  • Pacific Biosciences made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #1859 holding.
  • Keating Financial Advisory Services first reported a position in Pacific Biosciences in Q4 2025 and has held it in 3 quarters since.
  • Keating Financial Advisory Services's Pacific Biosciences position peaked at $2.81K in Q4 2025.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.